$MGNX News

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

MacroGenics Plans To Present Dose Escalation And Preliminary Tumor-Specific Cohort Results At The European Society For Medical Oncology Congress, October 23-27

MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?

Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval

How The MacroGenics (MGNX) Story Is Shifting With ADC Pipeline Bets And 2026 Data Risks

MacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates

How The MacroGenics (MGNX) Story Is Shifting With ADC Hopes And Execution Risks

MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are Pretty Bullish On The Stock After Recent Results

MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

Macrogenics Q1 EPS $(0.58) Beats $(0.65) Estimate, Sales $20.775M Beat $15.050M Estimate

GMP Manufacturing Sale Gives MacroGenics Additional Non-Dilutive Capital for Pipeline Development (MGNX)

MacroGenics Enters Into Expanded Royalty Purchase Agreement With Sagard In Exchange For Capped Royalty Interest On Future Global Net Sales Of ZYNYZ

Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble

MacroGenics Says FDA Removes Partial Clinical Hold On Phase 2 LINNET Study Of Lorigerlimab, Investigational, Bispecific DART Molecule That Targets PD-1 And CTLA-4

MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript